文献速递免疫规划卫生政策与健康促进

接种COVID-19 XBB.1.5疫苗后耳鸣风险:自身对照病例系列研究

Tinnitus risk after COVID-19 XBB.1.5 vaccination: A self-controlled case series study.
PubMed 文献 · Vaccine · 2025-07-26

该研究采用事件依赖性自身对照病例系列设计,在Kaiser Permanente南加州≥12岁人群中评估接种COVID-19 XBB.1.5疫苗(单独或与流感疫苗同时接种)后耳鸣风险。结果显示,接种后1-14天和1-28天风险区间内耳鸣风险未升高(RI分别为0.78和0.87),年龄和流感疫苗同时接种亚组分析亦无显著升高。结论提示接种COVID-19 XBB.1.5疫苗后耳鸣风险未增加。

要点

  • 接种COVID-19 XBB.1.5疫苗后1-14天耳鸣相对发病率为0.78(95%CI:0.67-0.90)。
  • 接种后1-28天耳鸣相对发病率为0.87(95%CI:0.78-0.96)。
  • 按年龄和流感疫苗同时接种状态分层,均未观察到耳鸣风险显著升高。

核心结论

  • 研究结果表明,接种COVID-19 XBB.1.5疫苗(单独或与流感疫苗同时接种)后耳鸣风险未增加,为COVID-19疫苗在耳鸣风险方面的安全性提供了令人安心的证据。

研究设计与样本

  • 采用事件依赖性自身对照病例系列(SCCS)设计,纳入Kaiser Permanente南加州≥12岁人群,耳鸣事件发生于2023年9月1日至2024年3月31日。
  • 暴露为Pfizer-BioNTech和Moderna COVID-19 XBB.1.5疫苗,伴或不伴流感疫苗同时接种。
  • 主要结局为首次耳鸣(2023年9月1日前无记录病史),次要结局为1年内首次耳鸣,通过住院、急诊和门诊ICD-10编码H93.1*识别。
  • 风险区间预先设定为接种后1-14天和1-28天,风险区间外的人时作为对照区间;通过纳入未接种COVID-19 XBB.1.5疫苗者的耳鸣事件及在SCCS模型中纳入日历月份调整季节性。

主要发现

  • 在COVID-19 XBB.1.5疫苗接种者中发生13,940例首次耳鸣事件,总体分析未观察到接种后1-14天或1-28天内风险升高。
  • 14天风险区间相对发病率(RI)为0.78(95%CI:0.67-0.90),28天风险区间RI为0.87(95%CI:0.78-0.96)。
  • 按年龄和流感疫苗同时接种状态进行的亚组分析亦未显示RI显著升高。
  • 1年内首次耳鸣的总体分析、年龄别分析及流感疫苗同时接种分析均未发现RI显著升高。

关键数值与推荐

  • 主要结局首次耳鸣的14天风险区间RI为0.78(95%CI:0.67-0.90),28天风险区间RI为0.87(95%CI:0.78-0.96)。
  • 次要结局1年内首次耳鸣在总体分析、年龄别分析及流感疫苗同时接种分析中均未发现RI显著升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While prior studies found no clear evidence of an association between COVID-19 vaccination and tinnitus, concerns about a potential link remain. This study assessed the risk of tinnitus following COVID-19 XBB.1.5 vaccination, administered alone or coadministered with influenza vaccine, using the event-dependent self-controlled case series (SCCS) design. METHODS: We conducted an SCCS study among individuals aged ≥12 years enrolled at Kaiser Permanente Southern California, with tinnitus events occurring between September 1, 2023, and March 31, 2024. The exposures included Pfizer-BioNTech and Moderna COVID-19 XBB.1.5 vaccines, with or without influenza vaccine coadministration. The primary outcome was first-ever tinnitus (no documented history before September 1, 2023), and the secondary outcome was first-in-1-year tinnitus, identified using ICD-10 code H93.1* in inpatient, emergency department, and outpatient settings. Risk intervals were pre-specified as 1-14 days and 1-28 days after vaccination, with person-time outside the risk interval serving as the control interval. Relative incidences (RI) and 95% confidence intervals (CI) were estimated, adjusting for seasonality by including tinnitus events among non-recipients of COVID-19 XBB.1.5 vaccines and by including calendar month in the SCCS models. RESULTS: With 13,940 first-ever tinnitus events among recipients of COVID-19 XBB.1.5 vaccines, no increased risk was observed within 1-14 or 1-28 days following vaccination in overall analyses. The RI was 0.78 (95% CI: 0.67-0.90) for the 14-day risk interval and 0.87 (95% CI: 0.78-0.96) for the 28-day interval. Subgroup analyses by age and influenza vaccine coadministration status also showed no significant increase in RI. Similarly, no significantly elevated RI was found for first-in-1-year tinnitus in the overall analyses, age-specific analyses, or analyses by coadministration with influenza vaccine. CONCLUSION: Our findings suggest no increased tinnitus risk following COVID-19 XBB.1.5 vaccination, either administered alone or coadministered with influenza vaccine. These results provide reassuring evidence of the safety of COVID-19 vaccines with respect to tinnitus risk.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Xu S, Sy LS, Hong V, et al. Tinnitus risk after COVID-19 XBB.1.5 vaccination: A self-controlled case series study. Vaccine. 2025. PMID: 40716143. doi:10.1016/j.vaccine.2025.127548

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。